Fabry disease in mice protects against lethal disease caused by Shiga toxin-expressing enterohemorrhagic Escherichia coli

Journal of Infectious Diseases

Volumn 194, Issue 8, 2006, Pages 1135-1140

  Cilmi, Salvatore A ^a   Karalius, Brad J ^a   Choy, Wendy ^a   Smith, R Neal ^a   Butterton, Joan R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA; ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID; SHIGA TOXIN; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENTEROBACTER INFECTION; ENTEROHEMORRHAGIC ESCHERICHIA COLI; FABRY DISEASE; FEMALE; GENE OVEREXPRESSION; GENOTYPE; HISTOPATHOLOGY; IMMUNOFLUORESCENCE MICROSCOPY; KIDNEY TUBULE NECROSIS; KNOCKOUT MOUSE; LYSOSOME; MALE; MOUSE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SPLEEN;

ADMINISTRATION, ORAL; ANIMALS; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; FABRY DISEASE; FEMALE; INJECTIONS, INTRAPERITONEAL; KIDNEY; MALE; MICE; MICE, KNOCKOUT; SHIGA TOXINS; TRIHEXOSYLCERAMIDES;

EID: 33749629725     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/507705     Document Type: Article

References (16)

1. Boyce T, Swerdlow D, Griffin P. Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med 1995; 333:364-8.
2. Griffin P. Escherichia coli O157:H7 and other enterohemorrhagic Escherichia coli. In: Blaser M, Smith P, Ravdin J, Greenberg H, Guerrant R, eds. Infections of the gastrointestinal tract. New York: Raven Press, 1995:739-61.
3. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichin coli infections. Clin Microbiol Rev 1998; 11:450-79.
4. Sheoran AS, Chapman-Bonofiglio S, Harvey BR, et al. Human antibody against Shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun 2005; 73:4607-13.
5. Nishikawa K, Matsuoka K, Watanabe M, et al. Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation. J Infect Dis 2005; 191:2097-105.
6. Ohshima T, Murray GJ, Swaim WD, et al. α-galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA 1997; 94:2540-4.
7. Ohshima T, Schiffmann R, Murray GJ, et al. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc Natl Acad Sci USA 1999; 96:6423-7.
8. Zeidner KM, Desnick RJ, Ioannou YA. Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit. Anal Biochem 1999; 267:104-13.
9. Wadolkowski EA, Burris JA, O'Brien AD. Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157: H7. Infect Immun 1990; 58:2438-45.
10. Wadolkowski EA, Sung LM, Burris JA, Samuel JE, O'Brien AD. Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. Infect Immun 1990; 58:3959-65.
11. Teel LD, Melton-Celsa AR, Schmitt CK, O'Brien AD. One of two copies of the gene for the activatable Shiga toxin type 2d in Escherichia coli O91:H21 strain B2F1 is associated with an inducible bacteriophage. Infect Immun 2002; 70:4282-91.
12. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. Fabry disease: preclinical studies demonstrate the effectiveness of α-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 2001; 68:14-25.
13. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073-86.
14. Lindgren SW, Melton AR, O'Brien AD. Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model. Infect Immun 1993; 61:3832-42.
15. Tzipori S, Chow CW, Powell HR. Cerebral infection with Escherichia coli O157:H7 in humans and gnotobiotic piglets. J Clin Pathol 1988; 41:1099-103.
16. Fujii J, Kinoshita Y, Kita T, et al. Magnetic resonance imaging and histopathological study of brain lesions in rabbits given intravenous verotoxin 2. Infect Immun 1996; 64:5053-60.